HUTCHMED starts Phase Ia trial of HMPL-A830 in advanced solid tumors
GSK•HUTCHMED began a Phase Ia trial of HMPL-A830 in China and the U.S. in September 2026. Its license agreement with GSK includes $110 million upfront, up to $1.19 billion in milestone payments and tiered royalties.
1. Trial begins
A Phase Ia trial of HMPL-A830 began in China and the U.S. in September 2026, enrolling patients with advanced solid tumors. The experimental therapy targets EGFR-expressing tumors with a KRAS inhibitor.
2. License agreement
HUTCHMED closed a license agreement with GSK, granting worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan. The deal provides $110 million upfront, up to $1.19 billion in milestone payments and tiered royalties on annual net sales. HUTCHMED’s subsidiary will handle global Phase I development, while GSK’s subsidiary will lead subsequent clinical development and commercialization in its licensed territory.
